Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR3110)
Drug Name
CC-122
Synonyms
cc-122; 1015474-32-4; Avadomide; 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione; CC122; CC 122; 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione; 2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-;2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-; Avadomide [USAN]; Avadomide(CC-122); Avadomide (USAN/INN); SCHEMBL282749; US9694015, Compound A; CHEMBL3989934; BDBM76986; RSNPAKAFCAAMBH-UHFFFAOYSA-N; EX-A1191; BCP15938; s7892; AKOS025399378; SB18829; CS-5995
Indication Brain cancer [ICD11: 2A00] Phase 1 [1]
Chronic lymphocytic leukaemia [ICD11: ICD11: 2A82] Phase 1 [2]
Diffuse large B-cell lymphoma [ICD11: ICD11: 2A81] Phase 1 [3]
Hepatocellular carcinoma [ICD11: ICD11: 2C12] Phase 1 [4]
Lymphoma [ICD11: ICD11: 2A80-2A86] Phase 1 [5]
Multiple myeloma [ICD11: ICD11: 2A83] Phase 1 [6]
Solid tumour/cancer [ICD11: ICD11: 2A00-2F9Z] Phase 1 [7]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 286.29 Topological Polar Surface Area 105
Heavy Atom Count 21 Rotatable Bond Count 1
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 5
Cross-matching ID
PubChem CID
24967599
CAS Number
1015474-32-4
TTD Drug ID
D03QZJ
Formula
C14H14N4O3
Canonical SMILES
CC1=NC2=CC=CC(=C2C(=O)N1C3CCC(=O)NC3=O)N
InChI
InChI=1S/C14H14N4O3/c1-7-16-9-4-2-3-8(15)12(9)14(21)18(7)10-5-6-11(19)17-13(10)20/h2-4,10H,5-6,15H2,1H3,(H,17,19,20)
InChIKey
RSNPAKAFCAAMBH-UHFFFAOYSA-N
The Predicted Metabolic Roadmap of This Drug
The Full List of Predicted Drug Metabolites (PDM) of This Drug
PDM Name PDM ID PubChem ID Reaction PDM Level Biosystem
CC-122 M1 PDM014440
24967958
Conjugation - N-Acetylation of arylamine 1 Human
CC-122 M2 PDM014542 N. A. Conjugation - Glucuronidation of primary aromatic amine 1 Human
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 1A2 (CYP1A2) DME0003 Homo sapiens
CP1A2_HUMAN
1.14.14.1
[8]
Cytochrome P450 3A (CYP3A) DMEN065 . Not Available Not Available [8]
References
1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 ClinicalTrials.gov (NCT01421524) Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma. U.S. National Institutes of Health.
8 Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.